Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04838054 · ClinicalTrials.gov registry record · Phase 4

The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Per-implant Mucositis

A Phase 4 study of Peri-implant Mucositis, sponsored by Rowpar Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
57
Enrollment target
1
Study location

NCT04838054 is a Phase 4 study of Peri-implant Mucositis that has completed, run by Rowpar Pharmaceuticals. The registered enrollment target is 57 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04838054, a Phase 4 study of Peri-implant Mucositis, has completed, sponsored by Rowpar Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

A full understanding of etiology and diagnosis of peri-implant diseases is crucial for finding effective treatments for these diseases that are more widely accessible to dentists. Several treatment protocols for peri-implant diseases have been proposed, but no gold standard has been established to date. Thus, the purpose of this study is to analyze efficacy of stabilized chlorine dioxide as a chemical adjuvant for treatment of peri-implant mucositis in a non-surgical treatment protocol with a 3-month follow-up.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Stabilized chlorine dioxide oral rinse

Study Locations (1)

New York

  • Stony Brook University - Stony Brook

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2018-03-15
Est. Completion 2020-03-04
Phase Phase 4

Sponsor

Rowpar Pharmaceuticals

2 total trials

What the Registry Record Tells You About NCT04838054

The ClinicalTrials.gov registry entry for NCT04838054 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rowpar Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peri-implant Mucositis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04838054 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04838054 about?

NCT04838054 is a clinical study titled "The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Per-implant Mucositis". A full understanding of etiology and diagnosis of peri-implant diseases is crucial for finding effective treatments for these diseases that are more widely accessible to dentists. Several treatment protocols for peri-implant diseases have been proposed, but no gold standard has been established to d...

What is the current status of trial NCT04838054?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. The study started on 2018-03-15. Estimated completion is 2020-03-04.

What conditions does trial NCT04838054 study?

This clinical trial studies the following conditions: Peri-implant Mucositis.

What interventions are being tested in trial NCT04838054?

The interventions under investigation include: Placebo (OTHER), Stabilized chlorine dioxide oral rinse (DRUG).

Who is sponsoring clinical trial NCT04838054?

This trial is sponsored by Rowpar Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04838054 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peri-implant Mucositis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.